ITM Charts A Path From Radionuclides To Radiotherapeutics And Attracts Financing
GEP-NET Candidate In Phase III
Interview: Germany’s ITM is executing on its plan to develop targeted radionuclide-based therapies with its lead lutetium-177 product in Phase III trials supported by a just closed $109m financing.
